The development of vaccines: how the past led to the future
SA Plotkin, SL Plotkin - Nature Reviews Microbiology, 2011 - nature.com
The history of vaccine development has seen many accomplishments, but there are still
many diseases that are difficult to target, and new technologies are being brought to bear on …
many diseases that are difficult to target, and new technologies are being brought to bear on …
Viral nanoparticles and virus‐like particles: platforms for contemporary vaccine design
EM Plummer, M Manchester - Wiley Interdisciplinary Reviews …, 2011 - Wiley Online Library
Current vaccines that provide protection against infectious diseases have primarily relied on
attenuated or inactivated pathogens. Virus‐like particles (VLPs), comprised of capsid …
attenuated or inactivated pathogens. Virus‐like particles (VLPs), comprised of capsid …
Insect cell technology is a versatile and robust vaccine manufacturing platform
Baculovirus and insect cell culture technologies have mostly been limited to research
laboratories for the transient expression of target proteins for drug development purposes …
laboratories for the transient expression of target proteins for drug development purposes …
A pan-HPV vaccine based on bacteriophage PP7 VLPs displaying broadly cross-neutralizing epitopes from the HPV minor capsid protein, L2
E Tumban, J Peabody, DS Peabody, B Chackerian - PloS one, 2011 - journals.plos.org
Background Current human papillomavirus (HPV) vaccines that are based on virus-like
particles (VLPs) of the major capsid protein L1 largely elicit HPV type-specific antibody …
particles (VLPs) of the major capsid protein L1 largely elicit HPV type-specific antibody …
Development of an AS04-adjuvanted HPV vaccine with the adjuvant system approach
N Garçon, S Morel, A Didierlaurent, D Descamps… - BioDrugs, 2011 - Springer
A novel human papillomavirus (HPV) vaccine has been formulated with virus-like particles of
the L1 protein of HPV-16 and HPV-18, and the Adjuvant System 04 (AS04). AS04 is a …
the L1 protein of HPV-16 and HPV-18, and the Adjuvant System 04 (AS04). AS04 is a …
Viral and non-viral approaches for transient delivery of mRNA and proteins
JW Schott, M Galla, T Godinho, C Baum… - Current gene …, 2011 - ingentaconnect.com
The transient delivery of gene products (RNA or proteins) is not a biotechnological invention
but rather an evolutionarily conserved process underlying and regulating a variety of …
but rather an evolutionarily conserved process underlying and regulating a variety of …
Prevention and treatment of papillomavirus-related cancers through immunization
IH Frazer, GR Leggatt… - Annual review of …, 2011 - annualreviews.org
Cervical and other anogenital cancers are initiated by infection with one of a small group of
human papillomaviruses (HPV). Virus-like particle-based vaccines have recently been …
human papillomaviruses (HPV). Virus-like particle-based vaccines have recently been …
Developments in virus-like particle-based vaccines for infectious diseases and cancer
L Buonaguro, M Tagliamonte… - Expert review of …, 2011 - Taylor & Francis
Virus-like particles hold great promise for the development of effective and affordable
vaccines. Indeed, virus-like particles are suitable for presentation and efficient delivery of …
vaccines. Indeed, virus-like particles are suitable for presentation and efficient delivery of …
Efficient production of chimeric Human papillomavirus 16 L1 protein bearing the M2e influenza epitope in Nicotiana benthamiana plants
Abstract Background Human papillomavirus 16 (HPV-16) L1 protein has the capacity to self-
assemble into capsomers or virus-like particles (VLPs) that are highly immunogenic …
assemble into capsomers or virus-like particles (VLPs) that are highly immunogenic …
New approaches to immunotherapy for HPV associated cancers
Cervical cancer is the second most common cancer of women worldwide and is the first
cancer shown to be entirely induced by a virus, the human papillomavirus (HPV, major …
cancer shown to be entirely induced by a virus, the human papillomavirus (HPV, major …